Richard Elion, MD
Director of Clinical Research
Whitman Walker Clinic
1701 14th Street Northwest
Washington, DC 20009, USA
Dr. Elion joined Whitman-Walker in 2006 as Clinical Research Director. He has been active in HIV care and research for 28 years, and he currently leads a team at Whitman-Walker that is focused on cutting-edge research initiatives in prevention and treatment of HIV/AIDS, Hepatitis C, and other STDs. Dr. Elion’s tenure at Whitman-Walker has coincided with the organization being selected in 2013 as part of the AIDS Clinical Trials Group by the National Institutes of Health (NIH), a distinguished honor for Whitman-Walker, and rare for a community health center.
Prior to joining Whitman-Walker Health, Dr. Elion served as co-director of HIV services at Washington Free Clinic, in private practice in Washington, D.C., and in various research and clinical capacities in New York and in Washington.
Dr. Elion received a bachelor’s degree in English and Psychobiology from Tufts University and a medical degree from Temple University. He completed his internship and residency at Duke University. He also holds a Master’s in Counseling and Spiritual Psychology from University of Santa Monica. In addition to his duties at Whitman-Walker, he is currently an associate clinical professor of Internal Medicine at George Washington University and at Johns Hopkins University.
His research interests include: HIV, Primary Medical Care.
PROFESSIONAL ORGANIZATIONS AND SOCIETIES
• American Medical Association
• American Public Health Association
• American Academy of Family Practice
• National Acupuncture Detoxification Association
• Community Research Initiative Alliance on AIDS
• American Academy of Medical Acupuncture (Founding Member)
1. Behrens G, Rijnders B, Nelson M, et al. Rilpivirine verses efavirenz with emtricitabine. Tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA<= 100,000 copies/mL: Week 96 pooled ECHO/THRIVE subanalysis. AIDS Patient Care STDS. 2014; 28(4): 168-175.
2. Soliman EZ, Roediger MP, Duprez DA, et al. Protease inhibitors and cardiac autonomic function in HIV- infected patients: across-sectional analysis from the strategies for management of antiretroviral therapy (smart) trial. BMJ Open. 2013; 3(3): e002523. doi: 10.1136/bmjopen-2012-002523
3. Elion R, Molina JM, Ramón Arribas López J, et al. A randomized phase 3 study comparing once daily elvitegravir with twice daily raltegravir in treatment experienced subjects with HIV-1 infection 96-week results. J Acquir Immune Defic Syndr. 2013; 63(4): 494-497. doi: 10.1097/QAI.0b013e318298469c
4. Elion R, Molina JM, Ramón Arribas López J, et al. A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment experienced subjects with HIV+infection 96-week results report. J Acquir Immune Defic Syndr. 2013; 63(4): 494-497.
5. Nelson M, Amaya G, Clumeck N, et al. Efficacy and safety of rilpivirine naive HIV-1 infected patients with hepatitis B virus/ hepatitis C virus coinfection enrolled in the phase iii randomized double blind ECHO and THRIVE trials. J Antimicrob Chemother. 2012; 67(8): 2020-2028. doi: 10.1093/jac/dks130
6.Elion R,Cohen C,Gathe J,et al.Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection. AIDS. 2011; 25(15): 1881-1886. doi: 10.1097/QAD.0b013e32834b4d48
7.Cohen C,Elion R,Ruane P,et al.Randomized,phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.AIDS2011; 25(6): F7-F12.doi: 10.1097/QAD.0b013e328345766f
8. Palella FJ Jr, Gange SJ, Benning L, et al. Inflammatory biomarkers and abacavir use in the womens interagency HIV study and the multicenter AIDS cohort study. AIDS. 2010; 24(11): 1657-1665. doi: 10.1097/QAD.0b013e3283389dfa
9. Ross LL, Rouse E, Gerondelis P, et al.Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine and atazanavir after discontinuation of ritonavir. J Antimicrob Chemother. 2010; 65(2): 307-315.
10. Elion R, Berger D, Richmond G, et al. Simplified maintenance therapy with abacavir/lamivudine and atazanavir after discontinuation of ritonavir. HIV Clin Trials. 2010; 11(3): 170-173. doi: 10.1310/hct1103-170
11. Ross LL, Rouse E, Gerondelis P, et al. Low abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir. J Antimicrob Chemother. 2010; 65(2): 307-315. doi: 10.1093/jac/dkp419
12. Baker J, Plankey M, Josayma Y, et al. The prevalence of rectal, urethral, and pharyngeal neisseria gonorrheae and chlamydia trachomatis among asymptomatic men who have sex with men in a prospective cohort in Washington, D.C. AIDS Patient Care STDS. 2009; 23(8): 585-588. doi: 10.1089/apc.2008.0277
13. Ross L, Elion R, Lanier R, et al. Modulation of K65R selection by zidovudine inclusion: Analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40623). AIDS Res Hum Retroviruses. 2009; 25(7): 665-672. doi: 10.1089/aid.2008.0302
14. Boyle BA, Cohen CJ, DeJesus E, et al. Select updates from the 16th CROI: Treatment-related cardiovascular risk, pharmacokinetic issues, and interleukin-2 use. AIDS Read. 2009; 19(4): 158-160.
15. Boyle BA, Cohen CJ, DeJesus E, et al. Antiretroviral therapy update from the 48th ICAAC/46th IDSA annual meeting. AIDS Read. 2009; 19(1): 22-31.
16. Boyle B, Cohen C, DeJesus E, et al. Antiretroviral treatment update from the 17th international AIDS conference. AIDS Read. 2008; 18(11): 570-579.
17. Elion R, Cohen C, Ward D, et al. Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naive patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/Emtricitabine given once daily. HIV Clin Trials. 2008; 9(4): 213-224.doi:10.1310/hct0904-213.
18. Gathe Jr. JC, Elion R. Antiretroviral rounds, resistance: What you dont know — cant hurt you? AIDS Clin Care. 2008; 20(6): 51-52.
19. Elion R, Dejesus E, Sension M, et al. Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral- naive patients: A48-week pilot study. HIV Clin Trials. 2008; 9(3): 152-163. doi: 10.1310/hct0903-152
20. Boyle BA, Elion R, Cohen CJ, DeJesus E, Hawkins T, Moyle GJ. Advances in HIV therapeutics: News from the 4th interenational AIDS society conference. AIDS Read. 2007; 17(10): 484-490.
21. Boyle BA, Elion R, Cohen CJ, Moyle GJ, Sax P, Frank I. Advances in HIV therapeutics: The 14th CROI. AIDS Read. 2007; 17(5): 268-270, 272-274, 283-286.
22. Elion R, Cohen C, DeJesus E, et al. Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naive subjects: A 48-week pilot study. HIV Clin Trials. 2006; 7(6): 324-333.
23. DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr. 2006; 43(1): 1-5.
24. Appelbaum JS, Elion R, Henry K, Newman MD, Saag MS, Sax PE. Roundtable, who should be providing HIV care? AIDS Clinical Care. 2006; 18(3): 21-24.
25. Boyle BA, Elion RA, Moyle GJ, Cohen CJ. Considerations in selecting protease inhibitor therapy. AIDS Rev. 2004; 6(4): 218-225.
26. Cohen C, Elion RA, Frank I, et al. Once-daily antiretroviral therapies for HIV infection: Consensus statement of an advisory committee of the international association of physicians in AIDS care. J Int Assoc Physicians AIDS Care (Chic). 2002; 1(4): 141-145.
27. Carter GM, Elion R, Kuebel M, et al.Supplementing antiretroviral therapy. Science. 2002; 297(5585): 1276.
28. Elion R, Kaul S, Knupp C, et al. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection. Clin Ther. 1999; 21(11): 1853-1863.
29. Elion R, Green L, Cohen C, et al. An open-label trial of stavudine, lamivudine and efavirenz in the treatment of HIV-positive, treatment-naive patients, and implications for clinical practice. Antivir Ther. 1999; 4 (Suppl 3): 89-91.
30. Wheeler DA, Gibert CL, Launer CA, et al. Weight loss as a predictor of survival and disease progression in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1998; 18(1): 80-85.
31. Elion RA, Cohen C. Complementary medicine and HIV infection. Prim Care. 1997; 24(4): 905-919.
32. Gay GR, Newmeyer JA, Elion RA, Wieder S. The sensuous hippie. Drug/sex practice in the haight ashbury. 1977; 6(1): 27-47.